Literature DB >> 2944942

Alzheimer's disease in Down's syndrome. A review.

H Karlinsky.   

Abstract

Alzheimer's disease is a progressive dementing illness accompanied by characteristic neuropathologic changes. Although its etiology is unknown, its risk of occurrence increases with age and in relatives of affected individuals. An additional risk factor is the presence of Down's syndrome. Almost all individuals with Down's syndrome over the age of 40 have the characteristic neuropathologic changes of Alzheimer's disease at autopsy. Although clinical evidence for Alzheimer's disease in Down's syndrome is less consistent, the association between Alzheimer's disease and Down's syndrome may contribute to an understanding of Alzheimer's disease in the general population. This article summarizes the neuropathologic and clinical observations of Alzheimer's disease in Down's syndrome and reviews the hypotheses that attempt to account for this association.

Entities:  

Mesh:

Year:  1986        PMID: 2944942     DOI: 10.1111/j.1532-5415.1986.tb04304.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  4 in total

1.  Human ETS2 gene on chromosome 21 is not rearranged in Alzheimer disease.

Authors:  N Sacchi; J Nalbantoglu; F R Sergovich; T S Papas
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

2.  Olfactory function in young adolescents with Down's syndrome.

Authors:  D A McKeown; R L Doty; D P Perl; R E Frye; I Simms; A Mester
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

3.  The relationship between enlargement of the temporal horns of the lateral ventricles and dementia in aging patients with Down syndrome.

Authors:  M LeMay; N Alvarez
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

Review 4.  Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.

Authors:  Syed Faraz Kazim; Khalid Iqbal
Journal:  Mol Neurodegener       Date:  2016-07-11       Impact factor: 14.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.